Literature DB >> 27235336

Survival of high-risk pediatric neuroblastoma patients in a developing country.

Joseph C Easton1,2, Sergio Gomez3, Peter H Asdahl4, J Michael Conner5, Alcira B Fynn3, Claudia Ruiz3, Rohit P Ojha1.   

Abstract

Little information is available about survival of high-risk pediatric neuroblastoma patients in developing countries. We aimed to assess survival among high-risk pediatric neuroblastoma patients in La Plata, Argentina. Individuals eligible for our cohort were aged <20 yr when diagnosed with high-risk neuroblastoma and received cancer-directed therapy including stem cell transplantation at Hospital de Niños Sor Maria Ludovica between February 1999 and February 2015. We estimated overall survival probabilities using an extended Kaplan-Meier approach. Our study population comprised 39 high-risk neuroblastoma patients, of whom 39% were aged >4 yr at diagnosis, 54% were male, and 62% had adrenal neuroblastoma. We observed 18 deaths, and the median survival time of our study population was 1.7 yr. The five-yr overall survival probability was 24% (95% CL: 10%, 41%). In contrast, five-yr survival of high-risk neuroblastoma patients ranges between 23% and 76% in developed countries. Survival among high-risk neuroblastoma patients is generally poor regardless of geographic location, but our results illustrate dramatically worse survival for patients in a developing country. We speculate that the observed survival differences could be attenuated or eliminated with improvements in treatment and supportive care, but addressing these issues will require creative solutions because of resource limitations.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  developing country; disparity; mortality; neuroblastoma; stem cell transplantation

Mesh:

Year:  2016        PMID: 27235336      PMCID: PMC5661966          DOI: 10.1111/petr.12731

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  27 in total

1.  Prevalence of hospital malnutrition in Latin America: the multicenter ELAN study.

Authors:  M Isabel T D Correia; Antonio Carlos L Campos
Journal:  Nutrition       Date:  2003-10       Impact factor: 4.008

2.  Value of surgical resection in children with high-risk neuroblastoma.

Authors:  Brian R Englum; Kristy L Rialon; Paul J Speicher; Brian Gulack; Timothy A Driscoll; Susan G Kreissman; Henry E Rice
Journal:  Pediatr Blood Cancer       Date:  2015-03-23       Impact factor: 3.167

3.  A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age.

Authors:  Sylvie Monnereau-Laborde; Caroline Munzer; Dominique Valteau-Couanet; Sophie Ansoborlo; Carole Coze; Pascal Chastagner; Hervé Rubie; François Demeocq; Jean-Louis Stephan; Olivier Hartmann; Yves Perel
Journal:  Pediatr Blood Cancer       Date:  2011-07-08       Impact factor: 3.167

4.  High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.

Authors:  Rani E George; Shuli Li; Cheryl Medeiros-Nancarrow; Donna Neuberg; Karen Marcus; Robert C Shamberger; Michael Pulsipher; Stephan A Grupp; Lisa Diller
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

Review 5.  Neuroblastoma: paradigm for precision medicine.

Authors:  Meredith S Irwin; Julie R Park
Journal:  Pediatr Clin North Am       Date:  2015-02       Impact factor: 3.278

Review 6.  Survival analysis in infectious disease research: describing events in time.

Authors:  Stephen R Cole; Michael G Hudgens
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

7.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

8.  Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation.

Authors:  T N Trahair; M R Vowels; K Johnston; R J Cohn; S J Russell; K A Neville; S Carroll; G M Marshall
Journal:  Bone Marrow Transplant       Date:  2007-08-27       Impact factor: 5.483

9.  High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.

Authors:  Jon Pritchard; Simon J Cotterill; Shirley M Germond; John Imeson; Jan de Kraker; David R Jones
Journal:  Pediatr Blood Cancer       Date:  2005-04       Impact factor: 3.167

10.  Retrospective analysis of peripheral blood stem cell transplantation for the treatment of high-risk neuroblastoma.

Authors:  Eun Kyung Kim; Hyoung Jin Kang; Jeong Ah Park; Hyoung Soo Choi; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

View more
  1 in total

1.  International Comparisons of Clinical Demographics and Outcomes in the International Society of Pediatric Oncology Wilms Tumor 2001 Trial and Study.

Authors:  Joaquim Caetano de Aguirre-Neto; Beatriz de Camargo; Harm van Tinteren; Christophe Bergeron; Jesper Brok; Gema Ramírez-Villar; Arnauld Verschuur; Rhoikos Furtwängler; Lisa Howell; Daniel Saunders; Oystein Olsen; Aurore Coulomb; Christian Vokuhl; Jan Godzinski; Anne M Smets; Gordan M Vujanic; Marry M van den Heuvel-Eibrink; Norbert Graf; Kathy Pritchard-Jones
Journal:  JCO Glob Oncol       Date:  2022-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.